BR112022021423A2 - Uso de proteína surfactante d para tratar infecções virais - Google Patents

Uso de proteína surfactante d para tratar infecções virais

Info

Publication number
BR112022021423A2
BR112022021423A2 BR112022021423A BR112022021423A BR112022021423A2 BR 112022021423 A2 BR112022021423 A2 BR 112022021423A2 BR 112022021423 A BR112022021423 A BR 112022021423A BR 112022021423 A BR112022021423 A BR 112022021423A BR 112022021423 A2 BR112022021423 A2 BR 112022021423A2
Authority
BR
Brazil
Prior art keywords
surfactant protein
viral infections
treat viral
treat
viral infection
Prior art date
Application number
BR112022021423A
Other languages
English (en)
Inventor
Kingma Paul
Grant Shawn
Arroyo-Rodríguez Raquel
Salzberg Marc
Original Assignee
Airway Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Airway Therapeutics Inc filed Critical Airway Therapeutics Inc
Publication of BR112022021423A2 publication Critical patent/BR112022021423A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/395—Alveolar surfactant peptides; Pulmonary surfactant peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

USO DE PROTEÍNA SURFACTANTE D PARA TRATAR INFECÇÕES VIRAIS. Algumas modalidades dos métodos e composições fornecidas neste documento referem-se ao uso da proteína surfactante D (SP-D) para tratar ou melhorar uma infecção viral em um indivíduo. Em algumas modalidades, a infecção viral compreende um coronavírus, como o coronavírus 2 da síndrome respiratória aguda grave (SARS-CoV-2). Algumas modalidades incluem o uso de certas formulações que compreendem uma SP-D humana recombinante (rhSP-D).
BR112022021423A 2020-04-22 2021-04-20 Uso de proteína surfactante d para tratar infecções virais BR112022021423A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063013726P 2020-04-22 2020-04-22
US202063072354P 2020-08-31 2020-08-31
PCT/US2021/028207 WO2021216584A1 (en) 2020-04-22 2021-04-20 Use of surfactant protein d to treat viral infections

Publications (1)

Publication Number Publication Date
BR112022021423A2 true BR112022021423A2 (pt) 2023-01-03

Family

ID=78270057

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022021423A BR112022021423A2 (pt) 2020-04-22 2021-04-20 Uso de proteína surfactante d para tratar infecções virais

Country Status (10)

Country Link
US (1) US20230181697A1 (pt)
EP (1) EP4138905A4 (pt)
JP (1) JP2023523253A (pt)
KR (1) KR20230019089A (pt)
AU (1) AU2021258178A1 (pt)
BR (1) BR112022021423A2 (pt)
CA (1) CA3180205A1 (pt)
IL (1) IL297362A (pt)
MX (1) MX2022013195A (pt)
WO (1) WO2021216584A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023145916A1 (ja) * 2022-01-31 2023-08-03 積水メディカル株式会社 肺サーファクタントプロテインを含む液状組成物、及びそれを含む免疫測定キット、並びに肺サーファクタントプロテインの保存安定性向上方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030221199A1 (en) * 1998-10-20 2003-11-27 Whitsett Jeffrey A. Surfactant protein D for the prevention and diagnosis of pulmonary emphysema
US8933032B2 (en) * 1998-10-20 2015-01-13 Children's Hospital Medical Center Surfactant protein D for the treatment of disorders associated with lung injury
NL2011626C2 (en) * 2013-10-17 2015-04-20 Stichting Tech Wetenschapp Novel polypeptide and uses thereof.
WO2020247675A1 (en) * 2019-06-06 2020-12-10 Spiritus Therapeutics, Inc. Methods for attenuating viral infection and for treating lung injury
KR102205028B1 (ko) * 2020-03-22 2021-01-20 (주)셀트리온 사스-코로나바이러스-2에 중화 활성을 갖는 결합 분자
US11123329B1 (en) * 2020-03-23 2021-09-21 Vicore Pharma Ab Use of angiotensin II type 2 receptor agonist
CN112481417B (zh) * 2020-12-24 2022-05-27 山西大学 新冠肺炎病毒分型及突变位点快速检测方法及试剂盒

Also Published As

Publication number Publication date
EP4138905A1 (en) 2023-03-01
KR20230019089A (ko) 2023-02-07
CA3180205A1 (en) 2021-10-28
MX2022013195A (es) 2023-01-05
US20230181697A1 (en) 2023-06-15
IL297362A (en) 2022-12-01
JP2023523253A (ja) 2023-06-02
WO2021216584A1 (en) 2021-10-28
AU2021258178A1 (en) 2022-11-17
EP4138905A4 (en) 2024-04-17

Similar Documents

Publication Publication Date Title
BR112022018819A2 (pt) Vacinas contra coronavírus e métodos de uso
BR112021024310A2 (pt) Peptidomiméticos para o tratamento de infecções por coronavírus e picornavírus
CL2016000240A1 (es) Composición inmunogénica de reovirus de peces (prv) que comprende ácido nucleico del prv; polipéptido; virus atenuado o inactivado del prv, uso de la composición inmunogénica que sirve para tratar afecciones de infeción por prv en un animal.
BR112022004397A2 (pt) Composições para tratamento bucal que compreendem beta ácidos de lúpulo e aminoácidos
AR030068A1 (es) Composiciones farmaceuticas para el tratamiento de condiciones dolorosas, inflamatorias y ulcerosas de superficies epiteliales humedas como por ejemplo mucositis, estomatitis y sindrome de behcet
BRPI1009842B8 (pt) uso de agonista de tlr9 e agonista de tlr2/6 na preparação de uma composição farmacêutica para tratamento, inibição ou atenuação de uma infecção microbiana, bem como composição farmaceuticamente aceitável compreendendo os referidos agonistas
ECSP22076862A (es) Compuestos antivirales y métodos para la administración de los mismos
BR112023020600A2 (pt) Método para tratar ou prevenir uma infecção, e, uso de um composto
BR112022017308A2 (pt) Composição que compreende lactoferrina e cepas bacterianas probióticas para uso oral com ação antiviral
BR112022010798A2 (pt) Derivado de metileno-naftaleno-éter de fenilisoxazolila, seu uso e composição farmacêutica compreendendo o mesmo
BR112021015751A2 (pt) Vetores de terapia genética para tratamento da doença de danon
BR112023002951A2 (pt) Compostos de fosfolipídio e usos destes
PE20090653A1 (es) Formulacion inmunogenica, porque comprende una cepa recombinante atenuada de mycobacterium, preferentemente la cepa recombinante bacilo de calmette y guerin (bcg), que expresa al menos una proteina o fragmento inmunogenico del virus respiratorio sinc
CL2021001044A1 (es) Uso de plasma y fracciones de plasma para mejorar el dolor, la cicatrización de heridas y la recuperación posoperatoria
BR112022016456A2 (pt) Formulações de anticorpos anti-tslp humanos e métodos de uso dos mesmos
BR112022025134A2 (pt) 5-amino-2,3-dihidro-1,4-ftalazinadiona, composição, combinação, e, método de tratamento de uma infecção coronaviral
BR112022021423A2 (pt) Uso de proteína surfactante d para tratar infecções virais
BR112022008497A2 (pt) Derivados terapêuticos da interleucina-22
CL2023000491A1 (es) Composiciones de erenumab y usos de las mismas (divisional de solicitud n° 02519-2020).
BR112015019568A2 (pt) Peptídeo isolado, composição compreendendo o mesmo e uso do mesmo
BR112021019845A2 (pt) Composições de vírus inativado e formulações de vacina contra zika
MX2020003473A (es) Nuevo inhibidor de proteina-cinasa-cinasa activada por mitogeno (mek) para el tratamiento de infecciones virales y bacterianas.
BR112022019207A2 (pt) Composições de vacina para coronavírus e métodos de uso das mesmas
UY39313A (es) Composiciones amortiguadoras para el tratamiento de infecciones virales transmitidas por el aire
CO2023016983A2 (es) Cepas bacterianas que tienen actividad fungicida, composiciones que las comprenden y uso de estas